Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385997924> ?p ?o ?g. }
- W4385997924 endingPage "115759" @default.
- W4385997924 startingPage "115759" @default.
- W4385997924 abstract "The combination of venetoclax (VEN) and azacitidine (AZA) has become the standard of care for acute myeloid leukemia (AML) patients who are ≥ 75 years or unfit for intensive chemotherapy. Though initially promising, resistance to the combination therapy is an issue and VEN + AZA-relapsed/refractory patients have dismal outcomes. To better understand the mechanisms of resistance, we developed VEN + AZA-resistant AML cell lines, MV4-11/VEN + AZA-R and ML-2/VEN + AZA-R, which show > 300-fold persistent resistance compared to the parental lines. We demonstrate that these cells have unique metabolic profiles, including significantly increased levels of cytidine triphosphate (CTP) and deoxycytidine triphosphate (dCTP), changes in fatty acid and amino acid metabolism and increased utilization and reliance on glycolysis. Furthermore, fatty acid transporter CD36 is increased in the resistant cells compared to the parental cells. Inhibition of glycolysis with 2-Deoxy-D-glucose re-sensitized the resistant cells to VEN + AZA. In addition, the VEN + AZA-R cells have increased levels of the antiapoptotic protein Mcl-1 and decreased levels of the pro-apoptotic protein Bax. Overexpression of Mcl-1 or knockdown of Bax result in resistance to VEN + AZA. Our results provide insight into the molecular mechanisms contributing to VEN + AZA resistance and assist in the development of novel therapeutics to overcome this resistance in AML patients." @default.
- W4385997924 created "2023-08-20" @default.
- W4385997924 creator A5008374158 @default.
- W4385997924 creator A5010440853 @default.
- W4385997924 creator A5010446878 @default.
- W4385997924 creator A5018071939 @default.
- W4385997924 creator A5018943067 @default.
- W4385997924 creator A5027520603 @default.
- W4385997924 creator A5037364310 @default.
- W4385997924 creator A5040504042 @default.
- W4385997924 creator A5048054959 @default.
- W4385997924 creator A5059912126 @default.
- W4385997924 creator A5061036650 @default.
- W4385997924 creator A5065869973 @default.
- W4385997924 creator A5073580285 @default.
- W4385997924 date "2023-10-01" @default.
- W4385997924 modified "2023-10-07" @default.
- W4385997924 title "Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms" @default.
- W4385997924 cites W1976856958 @default.
- W4385997924 cites W2003930446 @default.
- W4385997924 cites W2006067987 @default.
- W4385997924 cites W2019549706 @default.
- W4385997924 cites W2034773856 @default.
- W4385997924 cites W2059958613 @default.
- W4385997924 cites W2063441242 @default.
- W4385997924 cites W2066387472 @default.
- W4385997924 cites W2066404900 @default.
- W4385997924 cites W2072451938 @default.
- W4385997924 cites W2074847845 @default.
- W4385997924 cites W2088253442 @default.
- W4385997924 cites W2089532685 @default.
- W4385997924 cites W2097035477 @default.
- W4385997924 cites W2097375979 @default.
- W4385997924 cites W2100828789 @default.
- W4385997924 cites W2121369682 @default.
- W4385997924 cites W2140277032 @default.
- W4385997924 cites W2338674998 @default.
- W4385997924 cites W2347187110 @default.
- W4385997924 cites W2408171154 @default.
- W4385997924 cites W2412718576 @default.
- W4385997924 cites W2473447250 @default.
- W4385997924 cites W2514200009 @default.
- W4385997924 cites W2517675534 @default.
- W4385997924 cites W2560396365 @default.
- W4385997924 cites W2605114805 @default.
- W4385997924 cites W2605757478 @default.
- W4385997924 cites W2620804057 @default.
- W4385997924 cites W2712679337 @default.
- W4385997924 cites W2741462465 @default.
- W4385997924 cites W2761360410 @default.
- W4385997924 cites W2771708376 @default.
- W4385997924 cites W2773927148 @default.
- W4385997924 cites W2794049848 @default.
- W4385997924 cites W2794453923 @default.
- W4385997924 cites W2806128074 @default.
- W4385997924 cites W2883474345 @default.
- W4385997924 cites W2891248360 @default.
- W4385997924 cites W2899130161 @default.
- W4385997924 cites W2899472109 @default.
- W4385997924 cites W2901585624 @default.
- W4385997924 cites W2902413705 @default.
- W4385997924 cites W2909332447 @default.
- W4385997924 cites W2943489262 @default.
- W4385997924 cites W2943984860 @default.
- W4385997924 cites W2974182987 @default.
- W4385997924 cites W2981869008 @default.
- W4385997924 cites W2982555809 @default.
- W4385997924 cites W3000515035 @default.
- W4385997924 cites W3005564200 @default.
- W4385997924 cites W3006513842 @default.
- W4385997924 cites W3013447738 @default.
- W4385997924 cites W3024717660 @default.
- W4385997924 cites W3033696780 @default.
- W4385997924 cites W3048827006 @default.
- W4385997924 cites W3081275729 @default.
- W4385997924 cites W3090943432 @default.
- W4385997924 cites W3095977572 @default.
- W4385997924 cites W3103494704 @default.
- W4385997924 cites W3114785916 @default.
- W4385997924 cites W3116974172 @default.
- W4385997924 cites W3157575545 @default.
- W4385997924 cites W3170232908 @default.
- W4385997924 cites W4221058111 @default.
- W4385997924 cites W4304588193 @default.
- W4385997924 cites W4360856474 @default.
- W4385997924 cites W4386373791 @default.
- W4385997924 doi "https://doi.org/10.1016/j.bcp.2023.115759" @default.
- W4385997924 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37604291" @default.
- W4385997924 hasPublicationYear "2023" @default.
- W4385997924 type Work @default.
- W4385997924 citedByCount "0" @default.
- W4385997924 crossrefType "journal-article" @default.
- W4385997924 hasAuthorship W4385997924A5008374158 @default.
- W4385997924 hasAuthorship W4385997924A5010440853 @default.
- W4385997924 hasAuthorship W4385997924A5010446878 @default.
- W4385997924 hasAuthorship W4385997924A5018071939 @default.
- W4385997924 hasAuthorship W4385997924A5018943067 @default.
- W4385997924 hasAuthorship W4385997924A5027520603 @default.